Literature DB >> 26874530

Prostate Cancer Imaging with Novel PET Tracers.

Liza Lindenberg1,2, Peter Choyke3,4, William Dahut5,6.   

Abstract

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors. In addition, the complexity of various prostate cancer states also contributes to the challenges in evaluating suitable radiotracer candidates. We have highlighted nuclear medicine tracers that focus on mechanisms involved in bone metastasis, prostate cancer cell membrane synthesis, amino acid analogs, androgen analogs, and the prostate specific membrane antigen. Encouraging results with many of these innovative radiotracer compounds will not only advance diagnostic capabilities for prostate cancer but open opportunities for theranostic applications to treat this worldwide malignancy.

Entities:  

Keywords:  11C acetate; 11C/18F choline; 18F DCFBC; 18F DHT; 18F FACBC; 18F NaF; 68Ga PSMA

Mesh：

Substances：

Year:  2016        PMID： 26874530      PMCID： PMC6364683          DOI： 10.1007/s11934-016-0575-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  48 in total

1.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

Review 2.  A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.

Authors:  Maurits Wondergem; Friso M van der Zant; Tjeerd van der Ploeg; Remco J J Knol
Journal:  Nucl Med Commun       Date:  2013-10       Impact factor: 1.690

3.  Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.

Authors:  Asha Leisser; Konstatin Pruscha; Philipp Ubl; Wolfgang Wadsak; Marius Mayerhöfer; Markus Mitterhauser; Marcus Hacker; Gero Kramer; Shahrokh Shariat; Georgios Karanikas; Markus Hartenbach; Alexander R Haug
Journal:  Prostate       Date:  2015-08-18       Impact factor: 4.104

4.  Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry.

Authors:  Bruce E Hillner; Barry A Siegel; Lucy Hanna; Fenghai Duan; Anthony F Shields; R Edward Coleman
Journal:  J Nucl Med       Date:  2014-02-27       Impact factor: 10.057

5.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.

Authors:  Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

6.  18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients.

Authors:  Cristina Nanni; Riccardo Schiavina; Eugenio Brunocilla; Marco Borghesi; Valentina Ambrosini; Lucia Zanoni; Giorgio Gentile; Valerio Vagnoni; Daniele Romagnoli; Giuseppe Martorana; Stefano Fanti
Journal:  Clin Genitourin Cancer       Date:  2013-10-14       Impact factor: 2.872

7.  Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer.

Authors:  Tobias Maurer; Gregor Weirich; Margret Schottelius; Martina Weineisen; Benjamin Frisch; Asli Okur; Hubert Kübler; Mark Thalgott; Nassir Navab; Markus Schwaiger; Hans-Jürgen Wester; Jürgen E Gschwend; Matthias Eiber
Journal:  Eur Urol       Date:  2015-05-06       Impact factor: 20.096

8.  Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.

Authors:  Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

9.  Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Authors:  Hojjat Ahmadzadehfar; Kambiz Rahbar; Stefan Kürpig; Martin Bögemann; Michael Claesener; Elisabeth Eppard; Florian Gärtner; Sebastian Rogenhofer; Michael Schäfers; Markus Essler
Journal:  EJNMMI Res       Date:  2015-06-20       Impact factor: 3.138

10.  Value of fused 18F-Choline-PET/MRI to evaluate prostate cancer relapse in patients showing biochemical recurrence after EBRT: preliminary results.

Authors:  Arnoldo Piccardo; Francesco Paparo; Riccardo Piccazzo; Riccardo Picazzo; Mehrdad Naseri; Paolo Ricci; Andrea Marziano; Lorenzo Bacigalupo; Ennio Biscaldi; Gian Andrea Rollandi; Filippo Grillo-Ruggieri; Mohsen Farsad
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411
View more
  13 in total

1.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

Review 2.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

3.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Authors:  Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-31       Impact factor: 9.236

4.  Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.

Authors:  Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Boris Warwitz; Lorenza Scarpa; Llanos Geraldo Roig; Dorota Kendler; Elisabeth von Guggenberg; Jasmin Bektic; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

5.  Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

Authors:  Paige M Glumac; Joseph P Gallant; Mariya Shapovalova; Yingming Li; Paari Murugan; Shilpa Gupta; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Clin Cancer Res       Date:  2019-11-15       Impact factor: 12.531

6.  Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Mark K Buyyounouski; Peter L Choyke; Jesse K McKenney; Oliver Sartor; Howard M Sandler; Mahul B Amin; Michael W Kattan; Daniel W Lin
Journal:  CA Cancer J Clin       Date:  2017-02-21       Impact factor: 508.702

7.  Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis.

Authors:  Weili Ma; Jiwei Mao; Jianfeng Yang; Ting Wang; Zhen Hua Zhao
Journal:  Eur Radiol       Date:  2022-04-29       Impact factor: 5.315

Review 8.  [Focus on molecular imaging in prostate cancer].

Authors:  L Michaud; K A Touijer
Journal:  Prog Urol       Date:  2016-09-20       Impact factor: 0.915

9.  Ultrasmall Renally Clearable Silica Nanoparticles Target Prostate Cancer.

Authors:  Feng Chen; Kai Ma; Li Zhang; Brian Madajewski; Melik Z Turker; Fabio Gallazzi; Kiara Cruickshank; Xiuli Zhang; Pocharapong Jenjitranant; Karim A Touijer; Thomas P Quinn; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury
Journal:  ACS Appl Mater Interfaces       Date:  2019-11-13       Impact factor: 9.229

Review 10.  Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.

Authors:  Sandra Bednarova; Maria L Lindenberg; Maria Vinsensia; Chiara Zuiani; Peter L Choyke; Baris Turkbey
Journal:  Transl Androl Urol       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.